Bax inhibitor peptide V5

Research use only, not for human use.

A cell-permeable synthetic peptide inhibitor of Bax conformational change and mitochondrial translocation.

A cell-permeable synthetic peptide inhibitor of Bax conformational change and mitochondrial translocation; inhibits Bax-mediated apoptosis in vitro; inhibit anti-cancer drug-induced apoptosis in vitro; upregulats expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulates expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-kappaB-p65 by 10, 30, and nearly 50%, respectively, on pancreatic islets in a mouse model.

Bax inhibitor peptide V5 (BIP-V5; 0-50 μM) reduces cell death in STF-cMyc cells but not in SW620 or NCI-H23 cells. BIPV5 does not result in any significant effect on cell cycle arrest at the G2/M phase. V5 treatment upregulates expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulates expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively.

Bax inhibitor peptide V5 (BIP-V5; 100 μM) significantly improves islet function following isolation and improves islet graft function following transplantation in mice model.

Val-Pro-Met-Leu-Lys | BIP-V5

Angiogenesis

Bcl-2

Bcl-2

Cancer

——

579492-81-2

586.7875

C27H50N6O6S

>98% (HPLC)

DMSO: ≥ 30 mg/mL

CC(C)CC(C(=O)NC(CCCCN)C(=O)O)NC(=O)C(CCSC)NC(=O)C1CCCN1C(=O)C(C(C)C)N

L-Lysine, L-valyl-L-prolyl-L-methionyl-L-leucyl-

(-20℃)

With Ice Pack

≥ 2 years